Abstract Number: 2674 • ACR Convergence 2025
Pulmonary ultrasound findings and their relationship with clinical characteristics and myopathy antibodies in a cohort of patients with myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by muscular and systemic involvement, with interstitial lung disease (ILD) being a challenging problem.…Abstract Number: 1185 • ACR Convergence 2025
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…Abstract Number: 2438 • ACR Convergence 2025
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…Abstract Number: 2412 • ACR Convergence 2025
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…Abstract Number: 2400 • ACR Convergence 2025
Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that potentially affects any organ. Pulmonary diseases (PD) are common in SLE and cover several different…Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…Abstract Number: 2259 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…Abstract Number: 0673 • ACR Convergence 2025
Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study
Background/Purpose: Vasoactive-vasodilating drugs (VVD) are the cornerstone of the treatment of pulmonary arterial hypertension (PAH), a form of precapillary pulmonary hypertension (pPH) that represents a…Abstract Number: 2258 • ACR Convergence 2025
Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease
Background/Purpose: Pulmonary diseases are contributors to the morbidity and mortality of RA. Despite the recent surge in studies of RA-associated interstitial lung disease (RA-ILD), there…Abstract Number: 0621 • ACR Convergence 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…Abstract Number: 2249 • ACR Convergence 2025
Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
Background/Purpose: Interstitial lung disease (ILD) is the second leading cause of mortality in rheumatoid arthritis (RA) but often goes underdiagnosed due to its variable clinical…Abstract Number: 0622 • ACR Convergence 2025
Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
Background/Purpose: Shrinking Lung Syndrome (SLS) is a rare pulmonary complication of systemic lupus erythematosus (SLE), characterized by unexplained dyspnea, pleuritic chest pain, loss of lung…Abstract Number: 2141 • ACR Convergence 2025
Treatment of Refractory Still’s/Systemic Juvenile Idiopathic Arthritis Lung Disease with the bi-specific IL-1Beta/IL-18 neutralizing antibody MAS825
Background/Purpose: Despite major advances in the understanding, diagnosis, and treatment of Still’s disease (including Systemic Juvenile Idiopathic Arthritis, sJIA), many patients experience a refractory course.…
- 1
- 2
- 3
- …
- 14
- Next Page »
